HIV Prevention Drug Approved

The FDA approves the use of Truvada for those at high risk of HIV infection.

Written byHayley Dunning
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Truvada was originally approved by the US Food and Drug Administration in August 2004 for use alongside antiretroviral drugs by those who are HIV-positive. Now, the agency announced that the drug would also be approved for use in individuals who are at a high risk of contracting the virus, making it the first drug approved for HIV preventation.

"Today's approval marks an important milestone in our fight against HIV," said FDA Commissioner Margaret Hamburg in a press release yesterday (July 16).

The drug, which can reduce the risk of infection by up to 75 percent, can now be used by anyone engaging in sexual activity with HIV-positive partners. Some groups, however, are concerned that it may provide a false sense of security, and encourage risky behavior. The FDA stresses Truvada should only be used as part of a "comprehensive HIV prevention plan," including condom use, among other things. Furthermore, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies